目的观察雌激素对绝经后妇女糖耐量减低 (IGT)患者糖代谢、胰岛素敏感性及其转归的影响。方法将 62例绝经 1年以上的女性 IGT患者随机分为小剂量雌激素倍美力治疗组 (A组 )及非药物干预治疗组 (B组 )进行为期 1年的研究。结果倍美力治疗组比非药物干预治疗组糖尿病发生率明显减少 ,而 IGT向糖耐量正常 (NGT)人转化者则明显增多。与非药物干预治疗组比较 ,雌激素能改善空腹血糖、胰岛素敏感指数 ,降低血脂及体重指数。结论雌激素是安全、可靠的药物 ,可用于绝经后妇女 IGT患者的干预治疗 Objective To investigate the effects of estrogen on glucose metabolism, insulin sensitivity and prognosis in postmenopausal women with impaired glucose tolerance (IGT). Methods Sixty-two female IGT patients who had been in menopause for more than one year were randomly divided into low-dose estrogen-treated group (group A) and non-drug-treated group (group B) for one year. Results The results showed that the incidence of diabetes was significantly decreased in the Beometrid group compared with the non-drug-treated group, while those in IGT patients with normal glucose tolerance (NGT) were significantly increased. Compared with the non-drug intervention treatment group, estrogen can improve fasting blood glucose, insulin sensitivity index, lower lipids and body mass index. Conclusion Estrogen is a safe and reliable drug for the treatment of IGT in postmenopausal women